Brian Markison

2020

In 2020, Brian Markison earned a total compensation of $3.8M as President and Chief Executive Officer at RVL Pharmaceuticals plc, a 12% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$690,000
Salary$715,923
Stock Awards$2,427,930
Total$3,833,853

Markison received $2.4M in stock awards, accounting for 63% of the total pay in 2020.

Markison also received $690K in non-equity incentive plan and $715.9K in salary.

Rankings

In 2020, Brian Markison's compensation ranked 2,985th out of 13,090 executives tracked by ExecPay. In other words, Markison earned more than 77.2% of executives.

ClassificationRankingPercentile
All
2,985
out of 13,090
77th
Division
Manufacturing
1,160
out of 5,621
79th
Major group
Chemicals And Allied Products
436
out of 2,254
81st
Industry group
Drugs
378
out of 1,954
81st
Industry
Pharmaceutical Preparations
279
out of 1,459
81st
Source: SEC filing on April 26, 2021.

Markison's colleagues

We found three more compensation records of executives who worked with Brian Markison at RVL Pharmaceuticals plc in 2020.

2020

James Schaub

RVL Pharmaceuticals plc

Chief Operating Officer

2020

Tina deVries

RVL Pharmaceuticals plc

EVP, Research Development

2020

Christopher Klein

RVL Pharmaceuticals plc

General Counsel

News

You may also like